A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Dabigatran and Rosuvastatin in Healthy Male Subjects

Inclusion Criteria: 1. Signed informed consent in a language understandable to the subject prior to any study-mandated procedure. 2. Healthy male subject aged between 18 and 45 years (inclusive) at Screening. Exclusion Criteria: 1. Known hypersensitivity to daridorexant, rosuvastatin, and/or dabigatran etexilate, or treatments of the same class, or any of its/their excipients. 2. Any history of hemorrhagic disease, whether or not hereditary. 3. Any history of complications with bleeding after surgery or tooth extractions and/or frequent nasal, hemorrhoidal, or gingival bleeding. 4. Activated partial thromboplastin time (aPTT) and/or thrombin time (TT) \< 0.8 or \> 1.2 at Screening. 5. Clinically relevant findings on the physical examination at Screening. 6. Clinically relevant findings on 12-lead ECG, recorded after 5 min in a supine position at Screening. 7. Clinically relevant findings in clinical laboratory tests (hematology, coagulation, clinical chemistry, and urinalysis) at Screening.